CANSINOBIO (06185) announced that, in accordance with Chinese Accounting Standards for Business Enterprises, the Group expects to achieve operating revenue between RMB 1.04 billion and RMB 1.08 billion for the year ending December 31, 2025. This represents an increase of RMB 194 million to RMB 234 million compared to the same period last year, a year-on-year growth of 22.88% to 27.61%.

The Group anticipates a net profit attributable to the owners of the parent company in the range of RMB 24.5 million to RMB 29 million for the year ending December 31, 2025. This signifies a successful turnaround from a loss to a profit compared to the previous year.

For the same period, the Group expects a net loss attributable to the owners of the parent company, after excluding non-recurring gains and losses, to be between RMB 91 million and RMB 96 million.

During the reporting period, the Group consistently implemented its development strategy focused on innovation and commercialization. Its product, Menhycia™, China's first quadrivalent meningococcal conjugate vaccine, sustained continuous revenue growth.

Concurrently, the Group advanced its cost-reduction and efficiency-improvement initiatives, leading to effective control over various expenses. The coordination between production and sales was further optimized, resulting in an improved gross profit margin.

The overall profitability of the Group saw a significant enhancement, successfully achieving a positive net profit attributable to the owners of the parent company within this reporting period.

As the Group's R&D projects progressed rapidly and international collaborations were initiated during the reporting period, it secured increased government-specific grants and international special fund support. Consequently, a substantial amount of non-recurring income was generated in this reporting period.